Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Amortization - Intangibles (2019 - 2026)

Collegium Pharmaceutical has reported Amortization - Intangibles over the past 7 years, most recently at $55.5 million for Q4 2025.

  • For Q4 2025, Amortization - Intangibles changed 0.0% year-over-year to $55.5 million; the TTM value through Dec 2025 reached $221.9 million, up 34.23%, while the annual FY2025 figure was $221.9 million, 34.23% up from the prior year.
  • Amortization - Intangibles for Q4 2025 was $55.5 million at Collegium Pharmaceutical, roughly flat from $55.5 million in the prior quarter.
  • Over five years, Amortization - Intangibles peaked at $55.5 million in Q1 2025 and troughed at $16.8 million in Q1 2021.
  • A 5-year average of $36.8 million and a median of $37.5 million in 2023 define the central range for Amortization - Intangibles.
  • Biggest five-year swings in Amortization - Intangibles: skyrocketed 151.74% in 2022 and later dropped 18.37% in 2023.
  • Year by year, Amortization - Intangibles stood at $16.8 million in 2021, then skyrocketed by 151.74% to $42.3 million in 2022, then decreased by 18.37% to $34.5 million in 2023, then skyrocketed by 60.72% to $55.5 million in 2024, then rose by 0.0% to $55.5 million in 2025.
  • Business Quant data shows Amortization - Intangibles for COLL at $55.5 million in Q4 2025, $55.5 million in Q3 2025, and $55.5 million in Q2 2025.